ProPhase Labs (NASDAQ:PRPH) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

ProPhase Labs (NASDAQ:PRPH) released its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05), FiscalAI reports. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $5.69 million.

ProPhase Labs Price Performance

PRPH stock traded down $0.02 during trading on Wednesday, reaching $0.23. 1,516,876 shares of the company were exchanged, compared to its average volume of 5,463,713. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.93 and a current ratio of 0.96. The stock’s 50 day moving average price is $0.42 and its 200 day moving average price is $0.38. ProPhase Labs has a 52-week low of $0.22 and a 52-week high of $0.93. The company has a market cap of $9.70 million, a P/E ratio of -0.40 and a beta of -0.28.

Institutional Investors Weigh In On ProPhase Labs

An institutional investor recently bought a new position in ProPhase Labs stock. XTX Topco Ltd acquired a new stake in ProPhase Labs, Inc. (NASDAQ:PRPH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 102,506 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned about 0.25% of ProPhase Labs at the end of the most recent quarter. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of ProPhase Labs in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a research note on Saturday, September 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.